Loading...
•
Dec 31, 2024
Pacira Q4 2024 Earnings Report
Pacira BioSciences, Inc. reported its financial results for the fourth quarter and full-year of 2024, with total revenues of $187.3 million for the quarter.
Key Takeaways
Pacira BioSciences, Inc. reported a 3% increase in total revenues for the fourth quarter of 2024, reaching $187.3 million, compared to $181.2 million in the same period last year. The company's GAAP net income for the quarter was $16.0 million, or $0.35 per basic share. Full-year revenues for 2024 were $701.0 million, a 4% increase from 2023.
Fourth quarter revenues increased by 3% to $187.3 million.
GAAP net income for Q4 2024 was $16.0 million, or $0.35 per basic share.
Adjusted EBITDA for Q4 2024 was $62.5 million, a 4% decrease from the prior year.
The company initiated a share repurchase program with $125.0 million remaining on authorization.
Revenue by Segment
Forward Guidance
Pacira BioSciences, Inc. provided full-year 2025 financial guidance, projecting total revenue between $725 million and $765 million.
Positive Outlook
- Projected total revenue of $725 million to $765 million.
- Non-GAAP gross margin expected to be 76% to 78%.
- Non-GAAP R&D expense projected between $90 million and $105 million.
- Non-GAAP SG&A expense anticipated between $290 million and $320 million.
- Stock-based compensation estimated at $56 million to $61 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...